MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

CytomX Therapeutics Inc

Open

BrancheGesundheitswesen

0.73 1.39

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.69

Max

0.76

Schlüsselkennzahlen

By Trading Economics

Einkommen

13M

19M

Verkäufe

4.7M

38M

KGV

Branchendurchschnitt

1.595

57.333

EPS

0.23

Gewinnspanne

49.552

Angestellte

119

EBITDA

14M

18M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+294.74% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2.3M

49M

Vorheriger Eröffnungskurs

-0.66

Vorheriger Schlusskurs

0.73

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

CytomX Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Apr. 2025, 23:54 UTC

Heiße Aktien

Stocks to Watch: Alphabet, Intel, AppFolio

24. Apr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24. Apr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. Apr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24. Apr. 2025, 23:37 UTC

Top News

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24. Apr. 2025, 23:36 UTC

Top News

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24. Apr. 2025, 23:13 UTC

Top News
Ergebnisse

Google's Earnings Power Holds Up in Global Turbulence -- Update

24. Apr. 2025, 23:09 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24. Apr. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24. Apr. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24. Apr. 2025, 22:51 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24. Apr. 2025, 22:48 UTC

Top News

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24. Apr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24. Apr. 2025, 22:38 UTC

Market Talk
Ergebnisse

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24. Apr. 2025, 22:24 UTC

Ergebnisse

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24. Apr. 2025, 22:24 UTC

Ergebnisse

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24. Apr. 2025, 22:24 UTC

Market Talk
Ergebnisse

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24. Apr. 2025, 22:23 UTC

Ergebnisse

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24. Apr. 2025, 22:11 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

24. Apr. 2025, 22:11 UTC

Market Talk
Ergebnisse

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24. Apr. 2025, 22:09 UTC

Top News
Ergebnisse

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24. Apr. 2025, 22:00 UTC

Market Talk
Ergebnisse

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24. Apr. 2025, 21:39 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24. Apr. 2025, 21:24 UTC

Top News
Ergebnisse

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. Apr. 2025, 21:24 UTC

Top News
Ergebnisse

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24. Apr. 2025, 21:23 UTC

Top News
Ergebnisse

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24. Apr. 2025, 21:04 UTC

Ergebnisse

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24. Apr. 2025, 21:03 UTC

Ergebnisse

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24. Apr. 2025, 21:03 UTC

Ergebnisse

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24. Apr. 2025, 21:02 UTC

Ergebnisse

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer-Vergleich

Kursveränderung

CytomX Therapeutics Inc Prognose

Kursziel

By TipRanks

294.74% Vorteil

12-Monats-Prognose

Durchschnitt 3 USD  294.74%

Hoch 3.5 USD

Tief 2.5 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CytomX Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

2

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

0.6101 / 0.78Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.